We offer the complete pathology phase of standard in vivo safety (‘toxicology’) studies of pharmaceuticals, chemicals (according to OECD), nanoparticle, combined biomaterial-pharmaceuticals, as well as implant and device characterization according to ISO 10993.
Our experts welcome and provide you with full support to design the pathology phase of your particular study:
- non-GLP safety/efficacy studies: efficacy, pharmacological, lead optimization and comparison
- disease models and efficacy studies: transgenic mouse phenotyping or disease model development purposes
Our portfolio ranges from full tissue processing services, also of special materials such as hard tissue and medical device containing samples, to the final biomarker analysis of your choice. Additionally, we do offer on-site Necropsy service.
No matter which study phase you would like to carry out with us, we can analyze your tissue of interest on different levels:
- Histology
- Protein level: Immunocytochemistry & Immunohistochemistry
- mRNA level: In situ hybridization (ISH)
Further, we currently established DNA and RNA isolation from FFPE material for downstream analysis by Next Generation Sequencing (NGS).